Interestingly, the sensitivity and specificity of the cf-mtDNA/p-tau ratio to distinguish the diagnosis of AD was markedly higher in the core AD biomarker-selected cohort than in the unselected whole cohort (83% and 81% in biomarker-selected cohort vs 70% and 69% in whole cohort). Here, MAPT is linked to Alzheimer disease.